Last reviewed · How we verify
spironolactone, beta-blockers,ecc
This is a combination therapy using spironolactone (a potassium-sparing diuretic and aldosterone antagonist) and beta-blockers to reduce fluid retention, lower blood pressure, and decrease cardiac workload.
This is a combination therapy using spironolactone (a potassium-sparing diuretic and aldosterone antagonist) and beta-blockers to reduce fluid retention, lower blood pressure, and decrease cardiac workload. Used for Heart failure with reduced ejection fraction, Hypertension, Post-myocardial infarction management.
At a glance
| Generic name | spironolactone, beta-blockers,ecc |
|---|---|
| Sponsor | University of Roma La Sapienza |
| Drug class | Combination therapy: potassium-sparing diuretic + beta-adrenergic antagonist |
| Target | Aldosterone receptor (mineralocorticoid receptor) and beta-adrenergic receptors (β1, β2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Spironolactone blocks aldosterone receptors in the collecting duct, promoting sodium and water excretion while retaining potassium, thereby reducing blood volume and blood pressure. Beta-blockers reduce heart rate and contractility, decreasing cardiac oxygen demand and blood pressure. Together, these agents are commonly used in heart failure and hypertension management to improve outcomes and reduce neurohormonal activation.
Approved indications
- Heart failure with reduced ejection fraction
- Hypertension
- Post-myocardial infarction management
- Aldosteronism
Common side effects
- Hyperkalemia
- Fatigue
- Dizziness
- Bradycardia
- Gynecomastia (spironolactone)
- Hypotension
- Erectile dysfunction
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- spironolactone, beta-blockers,ecc CI brief — competitive landscape report
- spironolactone, beta-blockers,ecc updates RSS · CI watch RSS
- University of Roma La Sapienza portfolio CI